Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angela Alexander-Bryant has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An EGFR-Targeted Fusogenic Tandem Peptide for siRNA Delivery in Glioblastoma

    by Jessica R. Boulos, Karen E. Russi, Jordan Kinnitt, Daphne Gomez Escudero, Tyler Willis, Jorrian Abadeer, Emalee Mann, Aaron Cristina Anderson, Angela Alexander-Bryant

    Background/Objectives: RNA interference (RNAi) represents a promising therapeutic approach for silencing oncogenes involved in cancer progression by utilizing small interfering RNA (siRNA). However, siRNA requires an efficient delivery system to overcome cellular uptake and endosomal escape barriers. This study aimed to evaluate a multifunctional tandem peptide, GE11-599, designed to enhance the targeted delivery of siRNA and maintain its bioactivity in glioblastoma (GBM) cells. Methods: The GE11-599 peptide, consisting of an EGFR-targeting GE11 motif and a 599 fusogenic domain, was complexed with siRNA via electrostatic interactions to form nanoparticles. We assessed nanoparticle physicochemical properties, protection of siRNA from serum and RNase degradation, and cellular uptake in two GBM cell lines (U118MG and U87MG). Mechanistic studies evaluated receptor-mediated endocytosis and the subsequent escape from endosomes. Functional assays quantified STAT3 gene silencing and downstream effects on cell migration following treatment with GE11-599–siSTAT3 complexes. Results: GE11-599 formed positively charged, monodisperse nanoparticles capable of protecting siRNA from degradation. The tandem peptide significantly enhanced cellular internalization through EGFR-mediated endocytosis and facilitated endosomal escape of siRNA. Treatment with GE11-599–siSTAT3 resulted in robust gene silencing, achieving up to an 80% reduction in STAT3 mRNA expression. Downstream functional assessment showed a 40% decrease in migration in GBM cells treated with GE11-599–siSTAT3 complexes. Conclusions: The GE11-599 tandem peptide effectively enhances cell-specific internalization and endosomal escape of siRNA in GBM cells, resulting in increased siRNA bioactivity and functional gene silencing. These findings support GE11-599 as a promising siRNA delivery platform for targeting EGFR-expressing cancers.

  • Open Access

    Enabling in vivo imaging in low‐resource settings: Computed tomography imaging of gold‐loaded polymersomes for the detection of glioblastoma

    by Emily Barnett, Joey Lavalla, Pranavi Thatavarthi, Isabel Ray, Taylor Hamas, Jessica Jager, Vaishnavi Kanduri, Jasmine White, Elizabeth Singleton, Jordan Drinks, et al.

    Glioblastoma (GBM) is one of the most aggressive and rapidly progressing brain tumors, characterized by a low survival rate, in part due to insufficient diagnostic tools. Computed tomography (CT), although widely available, is limited in use for GBM diagnosis by the suboptimal performance of current clinically approved contrast agents. This study focuses on the development of gold nanoparticle (AuNP)‐loaded polymersomes (AuPs) to improve the detection of GBM. We synthesized polyethylene glycol‐b‐polylactic acid (PEG‐b‐PLA) polymersomes with high AuNP loading. Increasing the concentrations of AuNPs in polymersomes resulted in enhanced contrast using clinical CT. Furthermore, AuPs bound to cell‐penetrating peptide TAT were cytocompatible with U87‐MG GBM cells at concentrations up to 100 mg/mL. Uptake studies using both fluorescence microscopy and flow cytometry confirmed the internalization of AuPs into GBM cells, with a direct correlation between AuP concentration and uptake efficiency. MicroCT imaging also confirmed a similar trend; >300% enhanced contrast compared to PBS controls was observed with increasing concentrations of AuPs and was maintained in vivo at 337–863 HU. Overall, these results demonstrate that a polymersome‐based system for AuNPs enhances CT image contrast, suggesting that this approach could be feasible for improving GBM detection via CT.


  • Multifunctional Tandem Peptide Mediates Targeted siRNA Delivery to Ovarian Cancer Cells

    by Kharimat Lora Alatise, Timothy Samec, Carleigh Coffin, Serena Gilmore, Anthony Hazelton, Ruxi Xia, Chloe Jones, Angela Alexander-Bryant

    Fusogenic peptides have been developed to enhance the delivery efficiency of nucleic acids such as small interfering RNAs (siRNAs). Fusogenic peptides can protect nucleic acids from degradation and facilitate endosomal escape, but their systemic delivery capabilities remain unrefined. Active targeting of delivery systems to overexpressed cell receptors can be used to enhance cell- and tissue-specific delivery of therapeutic payloads while reducing off-target and systemic effects. We aimed to develop a targeted fusogenic (tandem) peptide, LHRHR-DIV3W, capable of targeting the luteinizing hormone-releasing hormone receptor (LHRHR), which is overexpressed in ovarian cancer cells and tissues. Characterization studies revealed that our tandem peptide, LHRHR-DIV3W, formed monodisperse nanocomplexes that protected siRNAs in physiological environments. We also demonstrated receptor-specific internalization of peptide-siRNA nanocomplexes in ovarian cancer cell lines with upregulated LHRHR expression. Furthermore, we observed that the inclusion of both the fusogenic DIV3W sequence and the LHRHR-targeting sequences in the tandem peptide enhanced receptor-specific siRNA internalization in ovarian cancer cells by up to 40% compared with the LHRHR-targeting peptide alone, indicating the necessity of combining both peptide regions. Finally, we demonstrated significant silencing of CSNK2A1, an oncogene overexpressed in ovarian cancer, in the ovarian cancer cell line OVCAR3. Our findings establish the use of a tandem peptide with cell-targeting and membrane-disruptive abilities as a delivery platform for nucleic acid therapies.


  • Open Access

    Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy

    by Thomas Eckert, M. S. Zobaer, Jessie Boulos, Angela Alexander-Bryant, Tiffany G. Baker, Charlotte Rivers, Arabinda Das, William A. Vandergrift, Jaime Martinez, Alicia Zukas, et al.

    Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.


  • Open Access

    Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets

    by Kharimat Lora Alatise, Samantha Gardner, Angela Alexander-Bryant

    In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, with ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer is the development of resistance to chemotherapeutics. While the exact mechanisms of chemoresistance are poorly understood, it is known that changes at the cellular and molecular level make chemoresistance challenging to treat. Improved therapeutic options are needed to target these changes at the molecular level. Using a precision medicine approach, such as gene therapy, genes can be specifically exploited to resensitize tumors to therapeutics. This review highlights traditional and novel gene targets that can be used to develop new and improved targeted therapies, from drug efflux proteins to ovarian cancer stem cells. The review also addresses the clinical relevance and landscape of the discussed gene targets.


  • Open Access

    Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer

    by Timothy Samec, Kharimat Lora Alatise, Jessica Boulos, Serena Gilmore, Anthony Hazelton, Carleigh Coffin, Angela Alexander-Bryant


  • Open Access

    De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells

    by Megan Pitz, Margaret Elpers, Alexandra Nukovic, Sarah Wilde, Arica Jordan Gregory, Angela Alexander-Bryant

    Glioblastoma multiforme (GBM) is the most aggressive central nervous system tumor, and standard treatment, including surgical resection, radiation, and chemotherapy, has not significantly improved patient outcomes over the last 20 years. Temozolomide (TMZ), the prodrug most commonly used to treat GBM, must pass the blood–brain barrier and requires a basic pH to convert to its active form. Due to these barriers, less than 30% of orally delivered TMZ reaches the central nervous system and becomes bioactive. In this work, we have developed a novel biomaterial delivery system to convert TMZ to its active form and that shows promise for intracellular TMZ delivery. Self-assembling peptides were characterized under several different assembly conditions and evaluated for TMZ loading and conversion. Both solvent and method of assembly were found to affect the supramolecular and secondary structure of peptide assemblies. Additionally, as peptides degraded in phosphate-buffered saline, TMZ was rapidly converted to its active form. This work demonstrates that peptide-based drug delivery systems can effectively create a local stimulus during drug delivery while remaining biocompatible. This principle could be used in many future biomedical applications in addition to cancer treatment, such as wound healing and regenerative medicine.


  • Open Access

    Peptide-based delivery of therapeutics in cancer treatment

    by Timothy Samec, Jessica Boulos, Serena Gilmore, Anthony Hazelton, Angela Alexander-Bryant


  • Factors Affecting Secondary and Supramolecular Structures of Self‐Assembling Peptide Nanocarriers

    by Megan E. Pitz, Alexandra M. Nukovic, Margaret A. Elpers, Angela A. Alexander‐Bryant

    Self‐assembling peptides are a popular vector for therapeutic cargo delivery due to their versatility, tunability, and biocompatibility. Accurately predicting secondary and supramolecular structures of self‐assembling peptides is essential for de novo peptide design. However, computational modeling of such assemblies is not yet able to accurately predict structure formation for many peptide sequences. This review identifies patterns in literature between secondary and supramolecular structures, primary sequences, and applications to provide a guide for informed peptide design. An overview of peptide structures, their applications as nanocarriers, and analytical methods for characterizing secondary and supramolecular structure is examined. A top‐down approach is then used to identify trends between peptide sequence and assembly structure from the current literature, including an analysis of the drivers at work, such as local and nonlocal sequence effects and solution conditions.


  • Open Access

    In Situ Photopolymerization of Acrylamide Hydrogel to Coat Cellulose Acetate Nanofibers for Drug Delivery System

    by Mohamed F. Attia, Ahmed S. Montaser, Arifuzzaman, Megan Pitz, Khouloud Jlassi, Angela Alexander-Bryant, Stephen S. Kelly, Frank Alexis, Daniel C. Whitehead

    In this study we developed electrospun cellulose acetate nanofibers (CANFs) that were loaded with a model non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, Ib) and coated with poly(acrylamide) (poly-AAm) hydrogel polymer using two consecutive steps: an electrospinning process followed by photopolymerization of AAm. Coated and non-coated CANF formulations were characterized by several microscopic and spectroscopic techniques to evaluate their physicochemical properties. An analysis of the kinetic release profile of Ib showed noticeable differences due to the presence or absence of the poly-AAm hydrogel polymer. Poly-AAm coating facilitated a constant release rate of drug as opposed to a more conventional burst release. The non-coated CANFs showed low cumulative drug release concentrations (ca. 35 and 83% at 5 and 10% loading, respectively). Conversely, poly-AAm coated CANFs were found to promote the release of drug (ca. 84 and 99.8% at 5 and 10% loading, respectively). Finally, the CANFs were found to be superbly cytocompatible.